De
Non vérifié

Debiopharm

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueOncologieSanté
20/10/2026
Science
Médecine - Divers
Santé Publique
Biotechnologie
Industrie pharmaceutique
Santé
Oncologie
Expos
Industrie
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma
1.00
14/10/2026
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Industrie
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance
1.00
01/09/2026
Marché du travail
Industrie
Science
Écologie/Santé environnementale
VIH, SIDA et maladies auto-immunes
Biotechnologie
Santé Publique
Industrie pharmaceutique
Santé
Oncologie
FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities
1.00
20/04/2026
Industrie
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer
1.00
14/04/2026
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Santé Publique
Debiopharm to Unveil New Pre-Clinical and Clinical Research Advances in DDR Inhibition, Dual Payload ADCs, and AI-Driven Biomarkers at AACR 2026
1.00
13/01/2026
Marché du travail
Industrie
Biotechnologie
Industrie pharmaceutique
Santé Publique
Santé
VIH, SIDA et maladies auto-immunes
Associations/Professionnels
Médecine - Divers
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug
1.00
04/12/2025
Industrie
Biotechnologie
Santé
Industrie pharmaceutique
Médecine - Divers
Santé Publique
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment
1.00
18/11/2025
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Marché du travail
Industrie
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program
1.00
06/11/2025
Industrie
Enfance
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
Science
Famille
Vitrines/Shopping
Médecine - Divers
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation
1.00
30/10/2025
Technique
Science
Biotechnologie
Santé
Industrie pharmaceutique
Oncologie
Marché du travail
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0